Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Colistin (Polymyxin E) vs Cosyntropin (Cortrosyn)
An educational, source-based comparison of Colistin (Polymyxin E) and Cosyntropin (Cortrosyn) — how each peptide works, what it's researched for, and what to know before going deeper.
Last-resort lipopeptide antibiotic for multidrug-resistant Gram-negatives.
Cationic cyclic lipopeptide that disrupts the outer membrane of Gram-negative bacteria by binding lipid A of LPS, causing membrane permeability and cell death.
- Carbapenem-resistant Acinetobacter, Klebsiella, Pseudomonas
- • FDA-approved.
- • Nephrotoxicity and neurotoxicity dose-limiting.
Synthetic peptide containing the first 24 amino acids of ACTH — retains full corticotropic activity. Stimulates adrenal cortisol release for diagnostic testing.
- Primary and secondary adrenal insufficiency diagnosis
- • FDA-approved.
- • Single diagnostic dose; very well tolerated.
Colistin (Polymyxin E) vs Cosyntropin (Cortrosyn) — Key differences
- Class: Colistin (Polymyxin E) is classified as Polymyxin · Infectious Disease, while Cosyntropin (Cortrosyn) is Diagnostic · Endocrine.
- Primary research focus: Colistin (Polymyxin E) — carbapenem-resistant acinetobacter, klebsiella, pseudomonas; Cosyntropin (Cortrosyn) — primary and secondary adrenal insufficiency diagnosis.
- Tag: FDA-Approved · Antibiotic vs FDA-Approved · Diagnostic.